Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. by Mathew, T et al.
AUTHOR COPY ONLY
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
© 2017 The British Society of Echocardiography www.echorespract.com
 Published by Bioscientifica Ltd
ID: 16-0037; June 2017
DOI: 10.1530/ERP-16-0037
Echocardiography in 
dilated cardiomyopathy
T Mathew and others
GuIDELINEs AND RECOMMENDATIONs
Diagnosis and assessment of dilated 
cardiomyopathy: a guideline protocol from the 
British Society of Echocardiography
Thomas Mathew1,a, Lynne Williams2,b, Govardhan Navaratnam3,b, Bushra Rana4,c, 
Richard Wheeler5,d, Katherine Collins6, Allan Harkness7, Richard Jones6, Dan Knight8, 
Kevin O’Gallagher9, David Oxborough10, Liam Ring11, Julie Sandoval12, Martin Stout13, 
Vishal Sharma14 and Richard P Steeds15, on behalf of the British Society of 
Echocardiography Education Committee
1Cardiology, Nottingham university Hospital, Nottingham, uK
2Cardiology, Papworth Hospital, Cambridge, uK
3university Health Board, Cwm Taf Health Board, Abercynon, uK
4Cardiac services Directorate, Papworth Hospital, Cambridge, uK
5Cardiothoracic, university Hospital of Wales, Cardiff, uK
6Cardiology, Portsmouth Hospitals NHs Trust, Queen Alexandra Hospital, Portsmouth, uK
7Cardiology Department, Colchester Hospital NHs Trust, Colchester, uK
8Centre for Cardiovascular Imaging, university College London, London, uK
9Cardiology, Kings College Hospital NHs Foundation Trust, London, uK
10Research Institute for sports and Exercise Physiology, Liverpool John Moores university, Liverpool, uK
11Cardiology Department, West suffolk Hospital NHs Trust, Bury st Edmonds, uK
12Cardiac ultrasound, Leeds Teaching Hospitals NHs Trust, Leeds, uK
13Cardiology Department, university Hospital south Manchester, Manchester, uK
14Cardiology, Royal Liverpool university Hospital, Liverpool, uK
15Cardiology, university Hospital Birmingham and university of Birmingham, Birmingham, uK
a(T Mathew is the Lead Author)
b(L Williams and G Navaratnam contributed equally)
c(B Rana is the Education Committee Chair)
d(R Wheeler is the Lead for Protocols)
Abstract
Heart failure (HF) is a debilitating and life-threatening condition, with 5-year survival rate 
lower than breast or prostate cancer. It is the leading cause of hospital admission in over 
65s, and these admissions are projected to rise by more than 50% over the next 25 years. 
Transthoracic echocardiography (TTE) is the first-line step in diagnosis in acute and chronic 
HF and provides immediate information on chamber volumes, ventricular systolic and 
diastolic function, wall thickness, valve function and the presence of pericardial effusion, 
while contributing to information on aetiology. Dilated cardiomyopathy (DCM) is the 
third most common cause of HF and is the most common cardiomyopathy. It is defined 
by the presence of left ventricular dilatation and left ventricular systolic dysfunction in 
the absence of abnormal loading conditions (hypertension and valve disease) or coronary 
artery disease sufficient to cause global systolic impairment. This document provides a 
practical approach to diagnosis and assessment of dilated cardiomyopathy that is aimed at 
the practising sonographer.
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1. Introduction
1.1. The BSE Education Committee has previously 
published a minimum dataset for a standard adult 
transthoracic echocardiogram (TTE). These are published 
online in Echo Research and Practice (1). This document 
specifically states that the minimum dataset is usually 
only sufficient when the echocardiographic study is 
entirely normal. The aim of the Education Committee is to 
publish a series of appendices to cover specific pathologies 
to support this minimum dataset. This final document 
completes the cardiomyopathy series (hypertrophic (2), 
restrictive (3), ARVC (4) and dilated cardiomyopathies).
1.2. The intended benefits of such supplementary 
recommendations are to:
•	 Support cardiologists and echocardiographers to 
develop local protocols and quality control programmes 
for adult transthoracic study.
•	 Promote quality by defining a set of descriptive terms and 
measurements, in conjunction with a systematic approach 
to perform and report a study in specific disease states.
•	 Facilitate the accurate comparison of serial 
echocardiograms performed in patients at the same or 
different sites.
1.3. The views and measurements are focussed upon 
dilated cardiomyopathy and are supplementary to those 
outlined in the TTE minimum dataset. This document 
gives recommendations for the image and analysis dataset 
required in patients either being assessed for or with a 
known diagnosis of dilated cardiomyopathy.
1.4. When the condition or acoustic windows of the 
patient prevent the acquisition of one or more 
components of the supplementary dataset or when 
measurements result in misleading information (e.g. off-
axis measurements) this should be stated.
1.5. This document is a guideline for echocardiography 
in dilated cardiomyopathy and will be updated in 
accordance with changes directed by publications or 
changes in practice.
2. Dilated cardiomyopathy
2.1. Dilated cardiomyopathy (DCM) is a progressive 
disease of the heart muscle. It is characterised by 
chamber enlargement and contractile dysfunction of the 
left ventricle in the absence of chronic pressure and/or 
volume overload. Although not essential for diagnosis, 
the right ventricle may similarly be affected. Dilated 
cardiomyopathy is the third most common cause of heart 
failure and is the commonest type of cardiomyopathy (5). 
The phenotype of ventricular dilatation and abnormal 
contractile dysfunction can be the result of a range of 
pathological conditions such as infection, toxins or 
autoimmune disease. However, in 50% of cases, the 
aetiology remains unknown and is termed ‘idiopathic 
DCM’. It is recognised that between 20% and 35% of 
idiopathic cases may have a family history suggesting an 
inherited gene defect (6).
2.2. Echocardiography is the first-line imaging test 
in the assessment of patients with DCM. It provides 
pivotal information not only for diagnosis, risk 
stratification and guiding treatment, but also plays a 
key role in screening family members. This document 
provides recommendations for the acquisition of 
images and collection of a dataset to be analysed during 
echocardiography in the assessment of patients with 
suspected or known DCM.
2.3. In this document, the parameters used for diagnosis 
and risk stratification are set out systematically 
(Table  1). Appendix 1 provides additional information 
on some of these parameters, Appendix 2 describes 
the echocardiographic features that help to differentiate 
the commonly encountered conditions presenting as 
DCM and finally a list of useful references for further 
reading.
2.4. The diagnostic criteria for DCM require exclusion of 
chronic pressure overload (such as hypertension and left 
ventricular outflow obstruction), chronic volume overload 
states (intra-cardiac shunts and valvular regurgitation) 
and ischaemic heart disease.
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Table 1 Parameters used for diagnosis and risk stratification.
View Measurements Explanatory note Image
PLAX 2D/M-
mode
LVIDd/s, IVsd, 
LVPWd
LV cavity size, wall thickness and 
radial function. Measurements are 
taken just distal to the mitral valve 
tip
If images are off axis, use 2D
All measurements should be indexed 
to BsA (refer to chamber 
quantification guidelines for normal 
values) (7)
 Fractional 
shortening (Fs) 
LVIDd >112% (2 s.d.) corrected for 
age and BSA is a diagnostic criterion 
for idiopathic DCM (refer to 
Appendix 1a)
Value above 117% (2 s.d. plus 5%) 
increases the specificity and may be 
useful as a screening tool
FS <25% is a criterion for the 
diagnosis of idiopathic DCM in the 
presence of a dilated ventricle
PLAX M-mode 
 
 
 
 
 
 
 
 
 
 
 
 
MV E-septal 
separation (EPss) 
 
 
 
 
 
 
 
 
 
 
 
EPss is defined as the minimal 
distance between E point (most 
anterior motion of the AML during 
diastole) and a line tangential to 
the most posterior excursion of the 
IVs within the same cardiac cycle
Normal range 0–5.3 mm. Value above 
7 mm is indicative of reduced systolic 
function but a normal value does 
not exclude LV dysfunction (8, 9) 
EPss in a normal ventricle
  
EPss in a patient with DCM
PLAX CFM Mitral 
regurgitation
Assess mechanism and severity of 
mitral regurgitation
 
  see Appendix 1a and MR dataset (10)  
(Continued)
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View Measurements Explanatory note Image
PsAX base to 
apex 2D
Qualitative 
assessment of 
ventricular (LV 
and RV) structure 
and function with 
special reference 
to radial systolic 
function and to 
exclude regional 
wall motion 
abnormalities
Refer to Appendix 2
A4C 2D Qualitative 
assessment of 
ventricular (LV 
and RV) structure 
and function with 
special reference 
to radial and 
longitudinal 
function and 
regional wall 
motion 
abnormalities
Refer to Appendix 2  
 LV volumes Diastolic and systolic volumes indexed 
to BsA (see BsE chamber 
quantification guide (7)). 3DE is 
recommended as the optimal 
method if endocardial definition is 
adequate
Consider use of echo contrast if poor 
endocardial definition
   
 
 
 
 
 
Ejection fraction 
(EF) 
 
 
 
 
Estimated using Bi-plane simpsons. 
3DE is the preferred modality for 
measurement of LVEF
EF of less than 45% is a diagnostic 
criterion for idiopathic DCM in the 
presence of a dilated ventricle  
(see Appendix 1a)
Table 1 Continued.
(Continued)
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View Measurements Explanatory note Image
 sphericity index 
(sI)
Ratio between the length (mitral 
annulus to apex in the apical view) 
and width (mid-cavity level in the 
A4C view
sI of 1.8 (d1/d2) in a non dilated LV with normal EF
   With gradual dilatation, left ventricle 
becomes more spherical in DCM and 
the value approaches near 1 (normal 
>1.5)
SI is a predictor of functional 
(exercise) capacity in patients with 
LV dysfunction and is an adverse 
prognostic marker (11)
sI of 1.2 in a patient with DCM
A4C CFM Mitral 
regurgitation
Assess mechanism and severity of MR
Refer to Appendix 1a and MR  
dataset (10)
A4C PW 
 
 
LV inflow Doppler 
 
 
E and A fusion is common in patients 
with DCM and indicates AV 
dysynchrony in the absence of sinus 
tachycardia
  
 
 
Table 1 Continued.
(Continued)
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View Measurements Explanatory note Image
 Diastolic 
dysfunction
In patients with EF less than 45%, 
diastolic dysfunction coexists. In this 
group, grading of diastolic 
dysfunction can be performed using 
mitral inflow pattern alone and 
provides additional prognostic 
information
See BSE diastolic function guidelines 
for further information (12)
Grade I
Grade II
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grade III
A4C tdi 
 
 
 
 
 
 
s and e′
Calculate E/e′ ratio 
 
 
 
Both are decreased in DCM
Refer to diastolic function guidelines 
for age adjusted values (9)
e′: an average from 2 sites (septal  
and lateral) is used for calculation of 
this ratio
Value above 13 suggests raised LA 
pressure (12)
Table 1 Continued.
(Continued)
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View Measurements Explanatory note Image
A5C PW 
 
 
 
 
 
 
 
 
 
 
 
Velocity time 
integral of LV 
outflow tract 
 
 
 
 
 
 
 
 
 
<18 cm is an adverse prognostic 
marker (13)
Indicative of a low flow state 
 
 
 
 
 
 
 
 
 
Focussed RV 
view 2D
Basal LV:RV ratio Qualitative assessment of RV size
A ratio of >0.66 suggests RV 
dilatation
  
 
 
 
 
 
 
 
 
 
 
 
RVD1
RVD2
RVD3 
 
 
 
 
 
 
 
 
 
RVD1 >41 mm; RVD2 >35 mm;  
RVD3 >83 mm indicates RV 
dilatation
Refer to BSE ARVC dataset for further 
information on RV measurements 
and assessment (4) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fractional area 
change (FAC) 
 
 
 
FAC of <35% indicates RV 
dysfunction 
RV dysfunction is not essential for 
the diagnosis of DCM but when 
present is an adverse prognostic 
marker (14)
Table 1 Continued.
(Continued)
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View Measurements Explanatory note Image
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Focussed RV 
view M-mode 
 
 
 
 
 
 
 
 
 
 
TAPsE 
 
 
 
 
 
 
 
 
 
 
 
TAPsE of <17 mm indicates RV systolic 
dysfunction 
 
 
 
 
 
 
 
 
 
 
Focussed RV 
view tdi
Tricuspid annulus s 
velocity
s velocity <9.5 cm/s indicates RV 
systolic dysfunction
Useful additional measurements
TR CW/CFM severity of TR and 
TR Vmax should 
be assessed in all 
views
see Appendix 1b
Raised PA pressure is an adverse 
prognostic marker (15)
 
LA 2D/M-mode 
 
 
 
 
 
 
 
LA dimension and 
volume 
 
 
 
 
 
 
Measured at end systole and  
BsA indexed.
LA dilatation suggests  
increased pressure and  
is an adverse prognostic  
marker (16) (please refer  
to BSE chamber quantification 
guidelines for reference  
values) (7)
  
 
 
 
 
 
 
 
Table 1 Continued.
(Continued)
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View Measurements Explanatory note Image
dp/dt CW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measured from MR 
jet indicates 
change in LV 
pressure over 
time during 
systole 
 
 
 
 
 
 
 
 
 
 
 
Record MR spectral profile at a high 
sweep speed (typically 100 mm/s). 
The time interval between the 
points at which the velocity is 1 m/s 
and 3 m/s is measured. According to 
the Bernoulli equation, the pressure 
increase in the left ventricle 
between these points is 32 mmHg 
(ΔP = 4 × V22 − 4 × V12 = 4 × 32 − 4 × 12).
Thus, dP/dt (in mmHg/s) is calculated 
from the following formula: 
LV dP/dt max = 32 mmHg/time (s)
dp/dt is a measure of global LV 
contractility
Normal value: 1000–1200 mmHg/s
dp/dt <600 mmHg/s is an adverse 
prognostic marker (17)
see Appendix 1d
 
  
 
 
 
  
Dysynchrony 
indices 
M-mode
septal to posterior 
wall delay
septal to posterior wall delay of more 
than 130 ms suggest intraventricular 
dysynchrony 
Value of more than 30 ms between 
right and left ventricular pre 
ejection time suggests inter 
ventricular dysynchrony
 
Dysynchrony 
indices PW
Difference 
between RV and 
LV ejection time
Average delay of more than 65 ms 
from onset of QRs to peak s wave 
from 4 basal segments suggests 
intra ventricular dysynchrony
 
Dysynchrony 
indices TDI 
 
Time from QRs 
onset to peak s 
wave from basal 
segments
Reduced aortic valve opening may be 
indicative of reduced stroke volume. 
However, if calcified may be due to 
primary AoV disease
  
 
 
Aortic valve 
M-mode
Pattern of aortic 
valve opening 
spontaneous contrast is commonly 
seen in dilated, poorly functioning 
chambers and should prompt 
assessment for intra cardiac 
thrombus
Thrombus 2D      
Table 1 Continued.
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Appendix 1: Important additional 
considerations
a. Diagnostic criteria: Diagnostic criteria of LV dilatation 
(>112% corrected to BSA and age) with reduced function 
(FS <25% and/or LVEF <45%) applies to ‘idiopathic’ 
DCM once secondary causes (hypertension, coronary 
artery disease, excess alcohol consumption, tachycardia-
induced cardiomyopathy, systemic or pericardial disease, 
cor pulmonale and congenital heart disease) have been 
excluded (18, 19, 20). The value of 117% is equivalent 
to 2 s.d. from the upper normal limit corrected to age 
and BSA plus 5%. For the purposes of this guideline, it 
is recommended that a value above 2 s.d.s for age, sex 
and BSA should be used in diagnosis, using linear and 
volumetric methods, whether 2D or 3D.
b. Mitral regurgitation: MR is common in patients with 
DCM and is due to disease of the ventricle rather than 
a primary lesion of the mitral valve leaflets. Functional 
MR results from tethering of the leaflets secondary to 
a change in LV geometry leading to a tenting pattern. 
Identification of the mechanism of MR is important 
because chronic MR due to primary mitral valve 
disease can also present with findings similar to DCM. 
Echocardiographic features that suggest functional MR 
include the following (in the absence of any obvious 
morphological abnormality of the leaflets):
1. symmetric tenting of leaflets (asymmetric is more 
commonly seen in ischaemic CMP)
2. reduced leaflet coaptation zone*
3. central jet of MR
4. increased coaptation depth*
5. increased tenting area*
6. dilated mitral valve annulus
 *see European Association of Cardiovascular Imag-
ing Valve Regurgitation Guidelines (21).
Transthoracic echocardiography usually differentiates 
primary from functional MR, but in a small proportion 
of patients, trans-oesophageal echocardiography may 
be required for further clarification.
c. Tricuspid regurgitation (TR): Functional TR in DCM is a 
marker of RV dilatation, RV dysfunction or pulmonary 
hypertension. Pulmonary artery pressure measured from 
TR velocity provides additional prognostic information 
in patients with DCM and should be assessed in all 
cases. Peak TR velocity of more than 2.5 m/s is associated 
with increased mortality, increased hospitalisation and 
higher incidence of heart failure (15).
d. Role of dysynchrony indices: Mechanical dysynchrony 
is common in patients with DCM and detection of 
Views  
 A2C Apical two chamber
 A4C Apical four chamber
 A5C Apical five chamber
 A3C Apical long axis or apical three chamber
 PLAX Parasternal long axis
 PsAX Parasternal short axis sC subcostal
 ssN suprasternal
Modality  
 CFM Colour flow Doppler
 CW Continuous wave Doppler PW Pulse wave 
Doppler
 TDI Tissue Doppler imaging
Explanatory test  
 2D 2-Dimensional echocardiography
 3DE 3-Dimensional echocardiography
 AML Anterior mitral valve leaflet
 ARVC Arrhythmogenic right ventricular 
cardiomyopathy
 AoV Aortic valve
 AV Atrio-ventricular
 BsA Body surface area
 BsE British society of Echocardiography
 CRT Cardiac resynchronisation therapy
 DCM dilated cardiomyopathy
 dp/dt LV pressure rise in systole divided by time 
(rate of pressure rise)
 e′ Early myocardial diastolic velocity on tissue 
Doppler imaging
 E/e′ Ratio of MV E Vmax/ tissue Doppler early 
myocardial relaxation velocity
 EF Ejection fraction
 EPss E point septal separation
 FAC Fractional area change
 Fs Fractional shortening
 ICM Ischaemic cardiomyopathy
 IVs Interventricular septum
 IVsd Interventricular septal thickness diastole
 LA Left atrium
 LV Left ventricle
 LVIDd Left ventricular internal dimension in 
diastole
 LVIDs Left ventricular internal dimension in systole
 LVNC Left ventricular non-compaction
 LVPWd Left ventricular posterior (inferolateral) wall 
thickness in diastole
 MR Mitral regurgitation
 RV Right ventricle
 RVD1 Right ventricular internal dimension
 sI sphericity index
 s′ Peak myocardial systolic velocity on tissue 
Doppler imaging
 TAPsE Tricuspid annular plane systolic excursion
 TR Tricuspid regurgitation
 PA Pulmonary artery
 RV Right ventricle
 RVD Right ventricular dimension
 RVsP Right ventricular systolic pressure
 TOE Trans-oesophageal echocardiography
Abbreviations
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dysynchrony is important to identify patients who 
may benefit from cardiac resynchronisation therapy 
(CRT). Several echocardiographic parameters have 
been used to assess mechanical dysynchrony in 
small subsets of patients; however, the wider role of 
echocardiography in selecting patients for CRT is 
still debated. Currently, the role of echo is limited to 
patients with borderline QRS duration (120–149 ms) 
in which the presence of inter or intraventricular 
dysynchrony may provide additional information (22). 
Assessment of dysynchrony is therefore not part of the 
routine dataset for patients with DCM and should be 
used as an option in selected cases only.
e. Stress echo and contractile reserve: Assessment of 
contractile reserve by low-dose dobutamine stress 
echocardiography may refine prognosis in patients 
with DCM and may be used when cardiopulmonary 
exercise stress testing is not available or in patients who 
are unable to exercise. An increase in LV EF from rest to 
peak stress by ≥5% or a percentage change from baseline 
of ≥20% indicates the presence of contractile reserve. 
Its absence is an adverse prognostic marker (23).
f. Role of echo in family screening: Asymptomatic first-
degree relatives of patients with idiopathic DCM 
should have an echocardiogram every 3–5  years or 
anytime signs or symptoms occur (24).
Appendix 2: Other related cardiomyopathic 
conditions
a. Ischaemic cardiomyopathy (ICM): Ischaemic 
cardiomyopathy can be differentiated from dilated 
cardiomyopathy by echocardiography in the vast 
majority of cases. LV dilatation in ICM usually 
occurs due to adverse remodelling after transmural 
myocardial infarction. During echocardiography, this is 
manifested by thinned, akinetic myocardial segments 
in the infarcted territory with cavity dilatation and 
mild compensatory hypertrophy of the non-infarcted 
segments. Infrequently, ICM can present as global 
hypokinesis mimicking DCM. When this occurs, it is 
usually in the presence of severe three-vessel coronary 
artery disease. In these situations, further assessment 
with stress echocardiography, stress cardiac MRI, 
coronary angiography or CT coronary angiography 
can be considered to exclude an ischaemic cause.
b. Left ventricular non-compaction cardiomyopathy 
(LVNC): LVNC is an unclassified cardiomyopathy and 
advanced cases can present with findings similar to 
DCM (i.e., a dilated and impaired left ventricle). 
Similarly, patients with DCM may have some 
echocardiographic features of LVNC which, 
if not recognised, can lead to over diagnosis. 
Echocardiographic criteria for the diagnosis of non-
compaction include (25):
1. A two-layer structure with a compacted epicardial 
and non-compacted endocardial layer with maximal 
end systolic ratio of non-compacted to compacted 
layers of >2.
2. Predominant localisation of pathology to the apex, 
mid-lateral and mid-inferior segments.
3. Colour Doppler evidence of blood flow amid the 
myocardial wall deep recesses and LV cavity.
4. Absence of any other coexisting cardiac abnormalities 
(e.g. primary valve disease).
c. Peri-partum cardiomyopathy (PPCM): PPCM is 
an idiopathic cardiomyopathy that presents with 
heart failure secondary to left ventricular systolic 
dysfunction; usually seen towards the end of pregnancy 
or in the first 5 months after delivery; in the absence 
of any other cause of heart failure. A reduction in LV 
EF (usually <45%) is required to establish the diagnosis 
but the left ventricle may or may not be dilated. Other 
features are similar to DCM.
d. Toxic causes: A number of substances can be directly 
toxic to cardiac myocytes and result in depressed 
cardiac function and a phenotype of DCM. Most 
common agents include alcohol and chemotherapeutic 
drugs used for the treatment of cancers. Alcoholic 
cardiomyopathy most typically affects men between 
the ages of 35 and 50 years although women can also 
be affected. There is usually a long and significant 
history of heavy alcohol use. In addition to standard 
heart failure treatment, it is essential that affected 
patients abstain completely from alcohol. If identified 
at an early stage, cardiac function can improve with 
abstinence from alcohol but if severe LV dysfunction 
has developed, the damage may be irreversible. 
Chemotherapeutic drugs such as trastuzumab 
(Herceptin), anthracyclines and cyclophosphamide are 
most commonly implicated in causing impaired LV 
function. Regular monitoring for cardiotoxicity with 
serial echocardiography is usually recommended, and 
the chemotherapeutic agent may need to be stopped or 
changed if signs of cardiotoxicity develop. In addition 
conditions that result in excess iron deposition within 
the heart can lead to a phenotype of DCM. These 
include conditions such as hemochromatosis (genetic 
condition that results in excessive iron absorption) 
or conditions in which repeated blood transfusions 
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are required (secondary iron overload). Treatment 
of this includes iron chelation agents, and in some 
cases, repeated venesection. Recreational drug use, 
particularly with cocaine can also result in DCM.
e. Viral/infective causes: Viral infection can result in 
acute and chronic myocarditis with myocyte death. In 
the acute phase, this can be occasionally very severe 
with the development of severe LV dysfunction, 
occasionally necessitating mechanical circulatory 
support or cardiac transplantation. It has also been 
suggested that viral persistence is implicated in the 
development of idiopathic DCM (26). Infection with 
human immunodeficiency virus (HIV) can result in 
a number of cardiac manifestations including the 
development of DCM. If DCM develops in the context 
of HIV, it carries a particularly unfavourable prognosis.
f. Systemic disease: A number of other systemic diseases 
can be associated with DCM. These include generalised 
muscles disease such as muscular dystrophy, connective 
tissue diseases and vasculitis. Again, the presence of 
cardiac involvement in these conditions is an adverse 
prognostic marker.
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